
Pierre Fabre SA licences immunotherapy from Atara Biotherapeutics
Paris-based Pierre Fabre Laboratories SA already held a licence for the EU-approved tabelecleucel, an allogeneic T cell based second-line treatment...

Cellectis and AstraZeneca in US$2.2bn deal
Under the co-development agreement, that includes a US$80m equity investment and an option for a further equity investment of US$140m by AstraZeneca...

Memo Therapeutics AG raises CHF25m
The CHF25m Series C round of Schlieren-based Memo Therapeutics AG was led by Pureos Bioventures. Existing investors Swisscanto, Vesalius Biocapital,...

VectorY Therapeutics raises €129m in Series A round
EQT Life Sciences and Forbion co-led the €129m Series A financing that will support clinical development of VectorY Therapeutics BVs lead...

Evotech screens cancer candidates for Dewpoint Therapeutics
With this partnership, the Hamburg-based screening specialists have landed a really big deal Dewpint Therapeutics, the just four-year-old spin-off...

Crucible Therapeutics spins out with £5m
Crucible Therapeutics Ltd., the newly launched spinout company from the University of Sheffield, secured the investment of £5m from Northern...